June 22, 2020 – Lantheus Holdings, Inc., the parent company of Lantheus Medical Imaging, Inc., announces completion of merger with Progenics Pharmaceuticals, Inc. Learn More
Improved diagnostic information for better patient management
Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting
Lantheus Completes Merger with Progenics
Lantheus Stockholders Approve Share Issuance For Merger with Progenics
Providng you with important information regarding our response to the
C0VID-19 pandemic.
(updated 5/29/2020)
View a recent Lantheus webinar:
COVID-19: Clinical Experiences from the Front Line in NYC
Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting
Lantheus Completes Merger with Progenics
Lantheus Stockholders Approve Share Issuance For Merger with Progenics
At Lantheus, we develop, manufacture and commercialize essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.
We are developing next generation imaging agents to enhance the accuracy, reliability and safety of diagnostic imaging.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.